Fumarate hydratase-deficient renal cell carcinoma - results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment.
Ahrens M, Haanen J, Albiges L, Goupil MG, Boleti E, Gravis G, Fléchon A, Grimm MO, Bedke J, Barthélémy P, Castellano D, Mellado B, Ivanyi P, Rottey S, Flörcken A, Suárez C, Maroto JP, Grünwald V, Oosting S, Kopecky J, Zschäbitz S, Boegemann M, Buchler T, Niegisch G, Goebell PJ, Waddell T, Joly F, Priou F, Retz M, Siemer S, Zimmermann U, Deckbar D, Burkholder I, Stöhr C, Hartmann A, Bergmann L; Interdisciplinary Renal Cell Carcinoma Working Group of the DKG (IAGN).
Ahrens M, et al. Among authors: flechon a.
Cancer Treat Res Commun. 2026 Jul 18;48:101319. doi: 10.1016/j.ctarc.2026.101319. Online ahead of print.
Cancer Treat Res Commun. 2026.
PMID: 42470850
Free article.